Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States.

Sydney R Resnik, Darren Targett, Barry I Resnik

Journal of drugs in dermatology : JDD 2023 Sep 01

filter terms:

Erythropoietic protoporphyria (EPP) is a rare disease that causes disabling cutaneous photosensitivity with pain and burning sensations. In 2019, afamelanotide, an α-melanocyte-stimulating hormone analogue, was approved in the United States for treatment of EPP. In this study, patients receiving afamelanotide filled out questionnaires assessing the benefit of treatment. Outcomes measured included: return to normal activities, experience of phototoxic reactions, effect on patient confidence, and more. Patients ranked their experience on a descriptive scale ranging from "very much" to "never". Prior to treatment, 75% of patients indicated that EPP affected their lives "very much" or "a lot". This number fell to 11% after the 1st implant and to 0% after each subsequent implant. The number of patients that willingly ventured outside increased with each subsequent implant. The results of this study clearly show that afamelanotide treatment can dramatically and positively impact the lives of EPP patients. Citation: Resnik SR, Targett D, Resnik BI. Into the light: afamelanotide and the treatment of erythropoietic protoporphyria in the United States. J Drugs Dermatol. 2023;22(9):941-949. doi:10.36849/JDD.7126R1.

Citation

Sydney R Resnik, Darren Targett, Barry I Resnik. Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States. Journal of drugs in dermatology : JDD. 2023 Sep 01;22(9):941-949